Still Waiting To Launch In U.S., NovaBay Sees Big Opportunity For Advanced Wound Care In Southeast Asia
This article was originally published in PharmAsia News
Executive Summary
While getting ready to launch FDA-approved wound-healing product NeutroPhase in the U.S., NovaBay also has expanded a commercialization partnership with Pioneer Pharma to add 13 Southeast Asian countries and territories to a collaboration once exclusive to China.